Gretai:6492

Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

TAIPEI, and SAN DIEGO, April 17, 2019 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell Carcinoma (BCC) has enrolled its first patient at Texas Oncology,Texas, USA. The trial will be carried o...

2019-04-17 19:00 142
123

Week's Top Stories

Most Reposted

TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia

[Picked up by 316 media titles]

2026-06-08 10:16
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia

DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership

[Picked up by 303 media titles]

2026-06-04 23:55
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership

Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia

[Picked up by 296 media titles]

2026-06-05 19:08
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia

DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion

[Picked up by 294 media titles]

2026-06-05 15:00

Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data

[Picked up by 284 media titles]

2026-06-08 09:00
Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data

Most Read

YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia

2026-06-05 19:37 9362
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia

Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)

2026-06-05 21:05 8304
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)

Tuniu Announces Unaudited First Quarter 2026 Financial Results

2026-06-05 18:00 8159

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

2026-06-05 22:00 7844
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS

2026-06-05 20:58 7579
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS